{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,30]],"date-time":"2026-10-30T20:35:14Z","timestamp":1793392514093,"version":"4.5.0"},"reference-count":53,"publisher":"Springer Science and Business Media LLC","issue":"12","license":[{"start":{"date-parts":[[2024,6,7]],"date-time":"2024-06-07T00:00:00Z","timestamp":1717718400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2024,6,7]],"date-time":"2024-06-07T00:00:00Z","timestamp":1717718400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Mol Psychiatry"],"published-print":{"date-parts":[[2024,12]]},"DOI":"10.1038\/s41380-024-02613-6","type":"journal-article","created":{"date-parts":[[2024,6,7]],"date-time":"2024-06-07T14:01:36Z","timestamp":1717768896000},"page":"3722-3733","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":51,"title":["The metabolome-wide signature of major depressive disorder"],"prefix":"10.1038","volume":"29","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-3333-6737","authenticated-orcid":false,"given":"Rick","family":"Jansen","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3697-6617","authenticated-orcid":false,"given":"Yuri","family":"Milaneschi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniela","family":"Schranner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gabi","family":"Kastenmuller","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthias","family":"Arnold","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xianlin","family":"Han","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4653-0483","authenticated-orcid":false,"given":"Boadie W.","family":"Dunlop","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"name":"Mood Disorder Precision Medicine Consortium","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2004-2382","authenticated-orcid":false,"given":"A. John","family":"Rush","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rima","family":"Kaddurah-Daouk","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brenda W. J. H.","family":"Penninx","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,6,7]]},"reference":[{"key":"2613_CR1","doi-asserted-by":"publisher","first-page":"122","DOI":"10.1002\/ajmg.b.32680","volume":"180","author":"K MacDonald","year":"2019","unstructured":"MacDonald K, Krishnan A, Cervenka E, Hu G, Guadagno E, Trakadis Y. Biomarkers for major depressive and bipolar disorders using metabolomics: A systematic review. Am J Med Genet B Neuropsychiatr Genet. 2019;180:122\u201337.","journal-title":"Am J Med Genet B Neuropsychiatr Genet"},{"key":"2613_CR2","doi-asserted-by":"publisher","first-page":"409","DOI":"10.1016\/j.biopsych.2019.08.016","volume":"87","author":"M Bot","year":"2020","unstructured":"Bot M, Milaneschi Y, Al-Shehri T, Amin N, Garmaeva S, Onderwater GLJ, et al. Metabolomics Profile in Depression: A Pooled Analysis of 230 Metabolic Markers in 5283 Cases With Depression and 10,145 Controls. Biological Psychiatry. 2020;87:409\u201318.","journal-title":"Biological Psychiatry"},{"key":"2613_CR3","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-023-36231-7","volume":"14","author":"H Julkunen","year":"2023","unstructured":"Julkunen H, Cicho\u0144ska A, Tiainen M, Koskela H, Nybo K, M\u00e4kel\u00e4 V, et al. Atlas of plasma NMR biomarkers for health and disease in 118,461 individuals from the UK Biobank. Nat Commun. 2023;14:604.","journal-title":"Nat Commun"},{"key":"2613_CR4","doi-asserted-by":"publisher","first-page":"1171","DOI":"10.2337\/dc11-2055","volume":"35","author":"A Pan","year":"2012","unstructured":"Pan A, Keum N, Okereke OI, Sun Q, Kivimaki M, Rubin RR, et al. Bidirectional association between depression and metabolic syndrome: a systematic review and meta-analysis of epidemiological studies. Diabetes Care. 2012;35:1171\u201380.","journal-title":"Diabetes Care"},{"key":"2613_CR5","doi-asserted-by":"publisher","first-page":"18","DOI":"10.1038\/s41380-018-0017-5","volume":"24","author":"Y Milaneschi","year":"2019","unstructured":"Milaneschi Y, Simmons WK, van Rossum EFC, Penninx BW. Depression and obesity: evidence of shared biological mechanisms. Mol Psychiatry. 2019;24:18\u201333.","journal-title":"Mol Psychiatry"},{"key":"2613_CR6","doi-asserted-by":"publisher","first-page":"2383","DOI":"10.2337\/dc08-0985","volume":"31","author":"B Mezuk","year":"2008","unstructured":"Mezuk B, Eaton WW, Albrecht S, Golden SH. Depression and type 2 diabetes over the lifespan: a meta-analysis. Diabetes Care. 2008;31:2383\u201390.","journal-title":"Diabetes Care"},{"key":"2613_CR7","doi-asserted-by":"publisher","first-page":"613","DOI":"10.1002\/gps.1723","volume":"22","author":"K Van der Kooy","year":"2007","unstructured":"Van der Kooy K, van Hout H, Marwijk H, Marten H, Stehouwer C, Beekman A. Depression and the risk for cardiovascular diseases: systematic review and meta analysis. Int J Geriatr Psychiatry. 2007;22:613\u201326.","journal-title":"Int J Geriatr Psychiatry"},{"key":"2613_CR8","doi-asserted-by":"publisher","first-page":"7372","DOI":"10.1038\/s41380-021-01176-0","volume":"26","author":"HU Zacharias","year":"2021","unstructured":"Zacharias HU, Hertel J, Johar H, Pietzner M, Lukaschek K, Atasoy S, et al. A metabolome-wide association study in the general population reveals decreased levels of serum laurylcarnitine in people with depression. Mol Psychiatry. 2021;26:7372\u201383.","journal-title":"Mol Psychiatry"},{"key":"2613_CR9","doi-asserted-by":"crossref","unstructured":"van der Spek A, Stewart ID, K\u00fchnel B, Pietzner M, Alshehri T, Gau\u00df F, et al. Circulating metabolites modulated by diet are associated with depression. Mol Psychiatry. 2023;28:3874\u201387.","DOI":"10.1038\/s41380-023-02180-2"},{"key":"2613_CR10","doi-asserted-by":"publisher","first-page":"7393","DOI":"10.1038\/s41380-021-01188-w","volume":"26","author":"Y Milaneschi","year":"2021","unstructured":"Milaneschi Y, Kappelmann N, Ye Z, Lamers F, Moser S, Jones PB, et al. Association of inflammation with depression and anxiety: evidence for symptom-specificity and potential causality from UK Biobank and NESDA cohorts. Mol Psychiatry. 2021;26:7393\u2013402.","journal-title":"Mol Psychiatry"},{"key":"2613_CR11","doi-asserted-by":"publisher","first-page":"254","DOI":"10.1016\/j.jad.2022.03.070","volume":"307","author":"Y Milaneschi","year":"2022","unstructured":"Milaneschi Y, Arnold M, Kastenm\u00fcller G, Dehkordi SM, Krishnan RR, Dunlop BW, et al. Genomics-based identification of a potential causal role for acylcarnitine metabolism in depression. J Affect Disord. 2022;307:254\u201363.","journal-title":"J Affect Disord"},{"key":"2613_CR12","doi-asserted-by":"publisher","DOI":"10.1038\/s41398-019-0554-y","volume":"9","author":"Y Milaneschi","year":"2019","unstructured":"Milaneschi Y, Peyrot WJ, Nivard MG, Mbarek H, Boomsma DI, Penninx WJH. B. A role for vitamin D and omega-3 fatty acids in major depression? An exploration using genomics. Transl Psychiatry. 2019;9:219.","journal-title":"Transl Psychiatry"},{"key":"2613_CR13","doi-asserted-by":"publisher","first-page":"2321","DOI":"10.1038\/s41591-022-02046-0","volume":"28","author":"P Surendran","year":"2022","unstructured":"Surendran P, Stewart ID, Au Yeung VPW, Pietzner M, Raffler J, W\u00f6rheide MA, et al. Rare and common genetic determinants of metabolic individuality and their effects on human health. Nat Med. 2022;28:2321\u201332.","journal-title":"Nat Med"},{"key":"2613_CR14","doi-asserted-by":"publisher","first-page":"343","DOI":"10.1038\/s41593-018-0326-7","volume":"22","author":"DM Howard","year":"2019","unstructured":"Howard DM, Adams MJ, Clarke T-K, Hafferty JD, Gibson J, Shirali M, et al. Genome-wide meta-analysis of depression identifies 102 independent variants and highlights the importance of the prefrontal brain regions. Nature Neuroscience. 2019;22:343.","journal-title":"Nature Neuroscience"},{"key":"2613_CR15","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1016\/j.jad.2021.03.026","volume":"287","author":"BWJH Penninx","year":"2021","unstructured":"Penninx BWJH, Eikelenboom M, Giltay EJ, van Hemert AM, Riese H, Schoevers RA, et al. Cohort profile of the longitudinal Netherlands Study of Depression and Anxiety (NESDA) on etiology, course and consequences of depressive and anxiety disorders. J Affect Disord. 2021;287:69\u201377.","journal-title":"J Affect Disord"},{"key":"2613_CR16","doi-asserted-by":"publisher","first-page":"121","DOI":"10.1002\/mpr.256","volume":"17","author":"BWJH Penninx","year":"2008","unstructured":"Penninx BWJH, Beekman ATF, Smit JH, Zitman FG, Nolen WA, Spinhoven P, et al. The Netherlands Study of Depression and Anxiety (NESDA): rationale, objectives and methods. Int J Methods Psychiatr Res. 2008;17:121\u201340.","journal-title":"Int J Methods Psychiatr Res"},{"key":"2613_CR17","doi-asserted-by":"publisher","DOI":"10.1007\/s11306-018-1420-2","volume":"14","author":"KT Do","year":"2018","unstructured":"Do KT, Wahl S, Raffler J, Molnos S, Laimighofer M, Adamski J, et al. Characterization of missing values in untargeted MS-based metabolomics data and evaluation of missing data handling strategies. Metabolomics. 2018;14:128.","journal-title":"Metabolomics"},{"key":"2613_CR18","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1016\/0165-1781(86)90060-0","volume":"18","author":"AJ Rush","year":"1986","unstructured":"Rush AJ, Giles DE, Schlesser MA, Fulton CL, Weissenburger J, Burns C. The Inventory for Depressive Symptomatology (IDS): preliminary findings. Psychiatry Res. 1986;18:65\u201387.","journal-title":"Psychiatry Res"},{"key":"2613_CR19","doi-asserted-by":"publisher","first-page":"1381","DOI":"10.1249\/01.MSS.0000078924.61453.FB","volume":"35","author":"CL Craig","year":"2003","unstructured":"Craig CL, Marshall AL, Sjostrom M, Bauman AE, Booth ML, Ainsworth BE, et al. International physical activity questionnaire: 12-country reliability and validity. Med Sci Sports Exercise. 2003;35:1381\u201395.","journal-title":"Med Sci Sports Exercise"},{"key":"2613_CR20","doi-asserted-by":"publisher","first-page":"64","DOI":"10.1159\/000338636","volume":"82","author":"MM Gerrits","year":"2013","unstructured":"Gerrits MM, van Oppen P, van Marwijk HW, van der Horst H, Penninx BW. The impact of chronic somatic diseases on the course of depressive and anxiety disorders. Psychother Psychosom. 2013;82:64\u201366.","journal-title":"Psychother Psychosom"},{"key":"2613_CR21","doi-asserted-by":"publisher","first-page":"308","DOI":"10.1159\/000491933","volume":"87","author":"R Gaspersz","year":"2018","unstructured":"Gaspersz R, Lamers F, Beekman ATF, van Hemert AM, Schoevers RA, Penninx BWJH. The Impact of Depressive Disorder Symptoms and Subtypes on 6-Year Incidence of Somatic Diseases. Psychother Psychosom. 2018;87:308\u201310.","journal-title":"Psychother Psychosom"},{"key":"2613_CR22","doi-asserted-by":"publisher","first-page":"110","DOI":"10.1038\/s41591-019-0722-x","volume":"26","author":"J Liu","year":"2020","unstructured":"Liu J, Lahousse L, Nivard MG, Bot M, Chen L, van Klinken JB, et al. Integration of epidemiologic, pharmacologic, genetic and gut microbiome data in a drug-metabolite atlas. Nat Med. 2020;26:110\u20137.","journal-title":"Nat Med"},{"key":"2613_CR23","doi-asserted-by":"publisher","first-page":"597","DOI":"10.1002\/gepi.21998","volume":"40","author":"S Burgess","year":"2016","unstructured":"Burgess S, Davies NM, Thompson SG. Bias due to participant overlap in two-sample Mendelian randomization. Genet Epidemiol. 2016;40:597\u2013608.","journal-title":"Genet Epidemiol"},{"key":"2613_CR24","doi-asserted-by":"publisher","first-page":"658","DOI":"10.1002\/gepi.21758","volume":"37","author":"S Burgess","year":"2013","unstructured":"Burgess S, Butterworth A, Thompson SG. Mendelian randomization analysis with multiple genetic variants using summarized data. Genet Epidemiol. 2013;37:658\u201365.","journal-title":"Genet Epidemiol"},{"key":"2613_CR25","doi-asserted-by":"publisher","first-page":"304","DOI":"10.1002\/gepi.21965","volume":"40","author":"J Bowden","year":"2016","unstructured":"Bowden J, Davey Smith G, Haycock PC, Burgess S. Consistent Estimation in Mendelian Randomization with Some Invalid Instruments Using a Weighted Median Estimator. Genet Epidemiol. 2016;40:304\u201314.","journal-title":"Genet Epidemiol"},{"key":"2613_CR26","doi-asserted-by":"publisher","first-page":"512","DOI":"10.1093\/ije\/dyv080","volume":"44","author":"J Bowden","year":"2015","unstructured":"Bowden J, Davey Smith G, Burgess S. Mendelian randomization with invalid instruments: effect estimation and bias detection through Egger regression. Int J Epidemiol. 2015;44:512\u201325.","journal-title":"Int J Epidemiol"},{"key":"2613_CR27","doi-asserted-by":"publisher","first-page":"1783","DOI":"10.1002\/sim.7221","volume":"36","author":"J Bowden","year":"2017","unstructured":"Bowden J, Del Greco M F, Minelli C, Davey Smith G, Sheehan N, Thompson J. A framework for the investigation of pleiotropy in two-sample summary data Mendelian randomization. Stat Med. 2017;36:1783\u2013802.","journal-title":"Stat Med"},{"key":"2613_CR28","doi-asserted-by":"publisher","first-page":"693","DOI":"10.1038\/s41588-018-0099-7","volume":"50","author":"M Verbanck","year":"2018","unstructured":"Verbanck M, Chen C-Y, Neale B, Do R. Detection of widespread horizontal pleiotropy in causal relationships inferred from Mendelian randomization between complex traits and diseases. Nat Genet. 2018;50:693\u20138.","journal-title":"Nat Genet"},{"key":"2613_CR29","doi-asserted-by":"publisher","first-page":"e34408","DOI":"10.7554\/eLife.34408","volume":"7","author":"G Hemani","year":"2018","unstructured":"Hemani G, Zheng J, Elsworth B, Wade KH, Haberland V, Baird D, et al. The MR-Base platform supports systematic causal inference across the human phenome. Elife. 2018;7:e34408.","journal-title":"Elife"},{"key":"2613_CR30","doi-asserted-by":"publisher","first-page":"740","DOI":"10.1093\/ije\/dyq151","volume":"40","author":"BL Pierce","year":"2011","unstructured":"Pierce BL, Ahsan H, Vanderweele TJ. Power and instrument strength requirements for Mendelian randomization studies using multiple genetic variants. Int J Epidemiol. 2011;40:740\u201352.","journal-title":"Int J Epidemiol"},{"key":"2613_CR31","doi-asserted-by":"publisher","first-page":"1339","DOI":"10.1038\/s41588-019-0481-0","volume":"51","author":"K Watanabe","year":"2019","unstructured":"Watanabe K, Stringer S, Frei O, Umi\u0107evi\u0107 Mirkov M, de Leeuw C, Polderman TJC, et al. A global overview of pleiotropy and genetic architecture in complex traits. Nat Genet. 2019;51:1339\u201348.","journal-title":"Nat Genet"},{"key":"2613_CR32","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-020-71948-1","volume":"10","author":"LM Reynolds","year":"2020","unstructured":"Reynolds LM, Dutta R, Seeds MC, Lake KN, Hallmark B, Mathias RA, et al. FADS genetic and metabolomic analyses identify the \u22065 desaturase (FADS1) step as a critical control point in the formation of biologically important lipids. Sci Rep. 2020;10:15873.","journal-title":"Sci Rep"},{"key":"2613_CR33","doi-asserted-by":"publisher","first-page":"123","DOI":"10.1159\/000228999","volume":"55","author":"C Galli","year":"2009","unstructured":"Galli C, Calder PC. Effects of fat and fatty acid intake on inflammatory and immune responses: a critical review. Ann Nutr Metab. 2009;55:123\u201339.","journal-title":"Ann Nutr Metab"},{"key":"2613_CR34","doi-asserted-by":"publisher","first-page":"771","DOI":"10.1038\/nrn3820","volume":"15","author":"RP Bazinet","year":"2014","unstructured":"Bazinet RP, Lay\u00e9 S. Polyunsaturated fatty acids and their metabolites in brain function and disease. Nat Rev Neurosci. 2014;15:771\u201385.","journal-title":"Nat Rev Neurosci"},{"key":"2613_CR35","doi-asserted-by":"publisher","first-page":"155","DOI":"10.1038\/npp.2017.130","volume":"43","author":"CJ Hillard","year":"2018","unstructured":"Hillard CJ. Circulating Endocannabinoids: From Whence Do They Come and Where are They Going? Neuropsychopharmacology. 2018;43:155\u201372.","journal-title":"Neuropsychopharmacology"},{"key":"2613_CR36","doi-asserted-by":"crossref","unstructured":"zu Heringdorf DM. Lysophospholipids. In: Offermanns S, Rosenthal W, editors. Encyclopedia of Molecular Pharmacology. Berlin, Heidelberg: Springer; 2008. p. 710\u20136.","DOI":"10.1007\/978-3-540-38918-7_90"},{"key":"2613_CR37","doi-asserted-by":"publisher","first-page":"122","DOI":"10.1016\/j.jpba.2013.10.045","volume":"89","author":"S Chen","year":"2014","unstructured":"Chen S, Wei C, Gao P, Kong H, Jia Z, Hu C, et al. Effect of Allium macrostemon on a rat model of depression studied by using plasma lipid and acylcarnitine profiles from liquid chromatography\/mass spectrometry. J Pharm Biomed Anal. 2014;89:122\u20139.","journal-title":"J Pharm Biomed Anal"},{"key":"2613_CR38","doi-asserted-by":"publisher","first-page":"6497","DOI":"10.1007\/s00216-016-9768-5","volume":"408","author":"X Liu","year":"2016","unstructured":"Liu X, Li J, Zheng P, Zhao X, Zhou C, Hu C, et al. Plasma lipidomics reveals potential lipid markers of major depressive disorder. Anal Bioanal Chem. 2016;408:6497\u2013507.","journal-title":"Anal Bioanal Chem"},{"key":"2613_CR39","doi-asserted-by":"publisher","first-page":"e008278","DOI":"10.1161\/JAHA.117.008278","volume":"7","author":"P Chan","year":"2018","unstructured":"Chan P, Suridjan I, Mohammad D, Herrmann N, Mazereeuw G, Hillyer LM, et al. Novel Phospholipid Signature of Depressive Symptoms in Patients With Coronary Artery Disease. J Am Heart Assoc. 2018;7:e008278.","journal-title":"J Am Heart Assoc"},{"key":"2613_CR40","doi-asserted-by":"publisher","first-page":"2032","DOI":"10.3390\/ijms23042032","volume":"23","author":"B Pinto","year":"2022","unstructured":"Pinto B, Conde T, Domingues I, Domingues MR. Adaptation of Lipid Profiling in Depression Disease and Treatment: A Critical Review. Int J Mol Sci. 2022;23:2032.","journal-title":"Int J Mol Sci"},{"key":"2613_CR41","doi-asserted-by":"publisher","first-page":"1074","DOI":"10.1038\/s42003-022-04011-6","volume":"5","author":"P Baloni","year":"2022","unstructured":"Baloni P, Arnold M, Buitrago L, Nho K, Moreno H, Huynh K, et al. Multi-Omic analyses characterize the ceramide\/sphingomyelin pathway as a therapeutic target in Alzheimer\u2019s disease. Commun Biol. 2022;5:1074.","journal-title":"Commun Biol"},{"key":"2613_CR42","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1016\/j.jbior.2018.09.013","volume":"70","author":"G Wang","year":"2018","unstructured":"Wang G, Bieberich E. Sphingolipids in neurodegeneration (with focus on ceramide and S1P). Adv Biol Regul. 2018;70:51\u201364.","journal-title":"Adv Biol Regul"},{"key":"2613_CR43","doi-asserted-by":"publisher","first-page":"58","DOI":"10.3389\/fnmol.2020.00058","volume":"13","author":"Y Hao","year":"2020","unstructured":"Hao Y, Guo M, Feng Y, Dong Q, Cui M. Lysophospholipids and Their G-Coupled Protein Signaling in Alzheimer\u2019s Disease: From Physiological Performance to Pathological Impairment. Front Mol Neurosci. 2020;13:58.","journal-title":"Front Mol Neurosci"},{"key":"2613_CR44","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1016\/j.psyneuen.2017.10.005","volume":"87","author":"CS Thesing","year":"2018","unstructured":"Thesing CS, Bot M, Milaneschi Y, Giltay EJ, Penninx BWJH. Omega-3 and omega-6 fatty acid levels in depressive and anxiety disorders. Psychoneuroendocrinology. 2018;87:53\u201362.","journal-title":"Psychoneuroendocrinology"},{"key":"2613_CR45","doi-asserted-by":"publisher","first-page":"269","DOI":"10.1016\/j.jad.2016.08.011","volume":"205","author":"G Grosso","year":"2016","unstructured":"Grosso G, Micek A, Marventano S, Castellano S, Mistretta A, Pajak A, et al. Dietary n-3 PUFA, fish consumption and depression: A systematic review and meta-analysis of observational studies. J Affect Disord. 2016;205:269\u201381.","journal-title":"J Affect Disord"},{"key":"2613_CR46","doi-asserted-by":"publisher","first-page":"3801235","DOI":"10.1155\/2022\/3801235","volume":"2022","author":"T Accinni","year":"2022","unstructured":"Accinni T, Panfili M, Tarsitani L, Biondi M, Pasquini M, Maraone A. A Revision on the Effectiveness of Omega-3 Polyunsaturated Fatty Acids as Monotherapy in the Treatment of Major Depressive Disorder. Int J Clin Pract. 2022;2022:3801235.","journal-title":"Int J Clin Pract"},{"key":"2613_CR47","doi-asserted-by":"publisher","first-page":"102219","DOI":"10.1016\/j.plefa.2020.102219","volume":"164","author":"S Lamon-Fava","year":"2021","unstructured":"Lamon-Fava S, So J, Mischoulon D, Ziegler TR, Dunlop BW, Kinkead B, et al. Dose- and time-dependent increase in circulating anti-inflammatory and pro-resolving lipid mediators following eicosapentaenoic acid supplementation in patients with major depressive disorder and chronic inflammation. Prostaglandins Leukot Essent Fatty Acids. 2021;164:102219.","journal-title":"Prostaglandins Leukot Essent Fatty Acids"},{"key":"2613_CR48","doi-asserted-by":"publisher","first-page":"21m14074","DOI":"10.4088\/JCP.21m14074","volume":"83","author":"D Mischoulon","year":"2022","unstructured":"Mischoulon D, Dunlop BW, Kinkead B, Schettler PJ, Lamon-Fava S, Rakofsky JJ, et al. Omega-3 Fatty Acids for Major Depressive Disorder With High Inflammation: A Randomized Dose-Finding Clinical Trial. J Clin Psychiatry. 2022;83:21m14074.","journal-title":"J Clin Psychiatry"},{"key":"2613_CR49","doi-asserted-by":"publisher","first-page":"1818","DOI":"10.1001\/jama.2016.16435","volume":"316","author":"DN Kyriacou","year":"2016","unstructured":"Kyriacou DN, Lewis RJ. Confounding by Indication in Clinical Research. JAMA. 2016;316:1818\u20139.","journal-title":"JAMA"},{"key":"2613_CR50","doi-asserted-by":"publisher","first-page":"4243","DOI":"10.1021\/ac2006119","volume":"83","author":"K Yang","year":"2011","unstructured":"Yang K, Zhao Z, Gross RW, Han X. Identification and quantitation of unsaturated fatty acid isomers by electrospray ionization tandem mass spectrometry: a shotgun lipidomics approach. Anal Chem. 2011;83:4243\u201350.","journal-title":"Anal Chem"},{"key":"2613_CR51","first-page":"00055","volume":"S0006-3223","author":"E Davyson","year":"2023","unstructured":"Davyson E, Shen X, Gadd DA, Bernabeu E, Hillary RF, McCartney DL, et al. Metabolomic Investigation of Major Depressive Disorder Identifies a Potentially Causal Association With Polyunsaturated Fatty Acids. Biol Psychiatry. 2023;S0006-3223:00055\u20130.","journal-title":"Biol Psychiatry"},{"key":"2613_CR52","doi-asserted-by":"publisher","first-page":"858","DOI":"10.1001\/jama.2019.0556","volume":"321","author":"M Bot","year":"2019","unstructured":"Bot M, Brouwer IA, Roca M, Kohls E, Penninx BWJH, Watkins E, et al. Effect of Multinutrient Supplementation and Food-Related Behavioral Activation Therapy on Prevention of Major Depressive Disorder Among Overweight or Obese Adults With Subsyndromal Depressive Symptoms: The MooDFOOD Randomized Clinical Trial. JAMA. 2019;321:858\u201368.","journal-title":"JAMA"},{"key":"2613_CR53","doi-asserted-by":"publisher","first-page":"2385","DOI":"10.1001\/jama.2021.21187","volume":"326","author":"OI Okereke","year":"2021","unstructured":"Okereke OI, Vyas CM, Mischoulon D, Chang G, Cook NR, Weinberg A, et al. Effect of Long-term Supplementation With Marine Omega-3 Fatty Acids vs Placebo on Risk of Depression or Clinically Relevant Depressive Symptoms and on Change in Mood Scores: A Randomized Clinical Trial. JAMA. 2021;326:2385\u201394.","journal-title":"JAMA"}],"container-title":["Molecular Psychiatry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41380-024-02613-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41380-024-02613-6","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41380-024-02613-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,12,1]],"date-time":"2024-12-01T19:06:58Z","timestamp":1733080018000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41380-024-02613-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,6,7]]},"references-count":53,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2024,12]]}},"alternative-id":["2613"],"URL":"https:\/\/doi.org\/10.1038\/s41380-024-02613-6","relation":{"has-preprint":[{"id-type":"doi","id":"10.21203\/rs.3.rs-3127544\/v1","asserted-by":"object"}]},"ISSN":["1359-4184","1476-5578"],"issn-type":[{"value":"1359-4184","type":"print"},{"value":"1476-5578","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,6,7]]},"assertion":[{"value":"30 June 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 April 2024","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 May 2024","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 June 2024","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"AJR has received consulting fees from Compass Inc., Curbstone Consultant LLC, Emmes Corp., Evecxia Therapeutics, Inc., Holmusk, Johnson and Johnson (Janssen), Liva-Nova, Neurocrine Biosciences Inc., Otsuka-US; speaking fees from Liva-Nova, Johnson and Johnson (Janssen); and royalties from Guilford Press and the University of Texas Southwestern Medical Center, Dallas, TX (for the Inventory of Depressive Symptoms and its derivatives). He is also named co-inventor on two patents: U.S. Patent No. 7,795,033: Methods to Predict the Outcome of Treatment with Antidepressant Medication, Inventors: McMahon FJ, Laje G, Manji H, Rush AJ, Paddock S, Wilson AS; and U.S. Patent No. 7,906,283: Methods to Identify Patients at Risk of Developing Adverse Events During Treatment with Antidepressant Medication, Inventors: McMahon FJ, Laje G, Manji H, Rush AJ, Paddock S. M.A. and G.K. are co-inventors (through Duke University\/Helmholtz Zentrum M\u00fcnchen) on patents on applications of metabolomics in diseases of the central nervous system and hold equity in Chymia LLC and IP in PsyProtix and Atai that are exploring the potential for therapeutic applications targeting mitochondrial metabolism in depression. RKD is funded by National Institute on Aging [U19AG063744, U01AG061359, 1RF1AG058942, 1RF1AG057452, RF1AG051550, and R01AG046171] and National Institute of Mental Health [R01MH108348]. This funding enabled consortia that she leads including the Mood Disorder Precision Medicine Consortium, the Alzheimer\u2019s Disease Metabolomics Consortium, and the Alzheimer Gut Microbiome Project that contributed to acylcarnitine discoveries. She is an inventor on key patents in the field of Metabolomics and hold equity in Metabolon, a biotech company in North Carolina. In addition, she holds patents licensed to Chymia LLC and PsyProtix with royalties and ownership. The funders listed above had no role in the design and conduct of the study; collection, management, analysis, and interpretation of the data; preparation, review, or approval of the paper; and decision to submit the paper for publication. BWD has received research support from Acadia, Compass, Aptinyx, NIMH, Sage, Otsuka, and Takeda, and has served as a consultant to Greenwich Biosciences, Myriad Neuroscience, Otsuka, Sage, and Sophren Therapeutics. All the other authors declare no conflict of interest.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}